A multi cancer screening platform for fast and accurate early stage cancer detec...
A multi cancer screening platform for fast and accurate early stage cancer detection from urine samples
Globally, more than 18 million people are diagnosed with cancer each year and this number is set to exceed 22 million by 2030. According to the World Health Organization (WHO), about 50% of cancer deaths could be avoided by enabli...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
LAUREN
bLadder cAncer URine cEll aNalysis
3M€
Cerrado
PROSTATOR
Reliable urinary test for the diagnosis of prostate cancer
150K€
Cerrado
BLACANDI
BLACANDI can improve life quality and cut cost of diagnosing...
71K€
Cerrado
OneRNA4Bladder
Non invasive Cell Based Liquid Biopsy Platform for Bladder C...
4M€
Cerrado
ColoFast
Developing a Non Invasive Kit for Early Colorectal Cancer De...
3M€
Cerrado
CELLETEST
Liquid Biopsy blood test in lung cancer diagnosis and monito...
71K€
Cerrado
Información proyecto Cancersensing
Duración del proyecto: 3 meses
Fecha Inicio: 2019-11-29
Fecha Fin: 2020-02-29
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Globally, more than 18 million people are diagnosed with cancer each year and this number is set to exceed 22 million by 2030. According to the World Health Organization (WHO), about 50% of cancer deaths could be avoided by enabling early cancer detection. Unfortunately, the market is still lacking a general test, suitable for the whole population, for detecting any type of cancer before the presentation of symptoms. Current gold standard procedures are highly invasive and risky, specific for one cancer type, and highly expensive. These factors limit their adoption to suspected cancer cases – i.e., after the presentation of symptoms, delaying cancer diagnosis and contributing to the huge economic burden on healthcare systems.
To overcome this problem, MDB DIAGNOSIS GROUP LTD (‘MDBD’) has developed Cancersensing, a revolutionary accurate and rapid screening platform for early diagnosis of multiple cancers from a single urine sample. The platform includes a highly specific and sensitive test that measures cancer-related biomarkers present in the urine, and a diagnostic software suite powered by proprietary machine learning algorithms and reference databases. Cancersensing makes cancer detection in its early stage available to all, maximizing survival rates and quality of life for patients, and reducing treatment costs and the cancer-related economic and societal burden.
During the feasibility assessment, MDBD will establish a go-to-market strategy and a supply chain, and define further development plan. During the second phase of innovation project, MDBD will optimize the Cancersensing screening platform, and perform clinical validation activities with hospital partners in the EU to obtain regulatory approval for commercialization.